ArticleDiabetes, obesity, and cardiometabolic CARE
Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans.
Article in Diabetes, obesity, and cardiometabolic CARE. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical, economic, and social benefits and costs of evidence-based obesity treatment among commercially insured adults. RESEARCH DESIGN AND
methodsUsing a Markov-based microsimulation model, we projected 5-year clinical and economic outcomes of intensive lifestyle management, obesity medications, and metabolic/bariatric surgery, drawing on data from clinical trials, national surveys, and economic studies.
resultsThis analysis focused on 47.3 million commercially insured adults with obesity who lacked access to treatment through existing clinical pathways. Over 5 years, cumulative medical savings per person ranged from $2,908 for lifestyle intervention to $2,450-$7,304 for obesity medications and $12,001 for surgery among adults without preexisting diabetes or cardiovascular disease. At the population level, access to treatment would yield 5-year benefits of $9.7 billion in medical savings, $25.8 billion in productivity gains, $38.8 billion in quality-of-life value, and $29.6 billion in mortality-reduction benefits, requiring $44.7 billion in total investment. Combined benefits produced net social value of $59.1 billion, with a $2.35 return per dollar invested and positive returns as early as the second year.
conclusionsObesity treatment generates substantial social benefits through improved health outcomes and productivity gains. Medical and disability cost savings and workplace productivity improvements combined could recover 81% of treatment investment. Employees effectively finance coverage through premiums and reduced wages, and comprehensive benefit design that includes health outcomes and quality-of-life improvements more accurately reflects societal treatment value. Coverage decisions based solely on employer economic returns underestimate the full societal value of expanding coverage. Video 1.Video abstract48ed6990-a68e-4467-8080-ab264925c4c6doci250006video1.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.